
DERM Stock Forecast & Price Target
DERM Analyst Ratings
Bulls say
Journey Medical Corp has demonstrated significant market traction, with payer access for its products increasing from approximately 30% of commercial lives in May to around 65% by July, affecting over 100 million lives. Additionally, the uptick in prescriber adoption from about 660 in the first quarter to over 1,800 in the second quarter signifies a robust growth trajectory. Furthermore, established brand value, particularly for key products like Accutane, enhances consumer retention and aids in maintaining market share.
Bears say
Journey Medical Corp exhibits a concerning trend in its prescription volume, as evidenced by the significant decline in Accutane prescriptions from 93,000 in Q1 2024 to approximately 66,000 in Q1 2025, which may negatively impact overall revenue. The company faces notable risks, including heightened competitive pressure from both branded and generic treatments, slower than anticipated uptake of its product Emrosi, and potential reimbursement pushback by payers. Additionally, ongoing regulatory and clinical risks, along with potential challenges in managing cash burn and effectively scaling its sales force, further contribute to a bearish outlook for the stock.
This aggregate rating is based on analysts' research of Journey Medical Corp and is not a guaranteed prediction by Public.com or investment advice.
DERM Analyst Forecast & Price Prediction
Start investing in DERM
Order type
Buy in
Order amount
Est. shares
0 shares